| Name | 9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α |
|---|---|
| Synonyms |
(5Z)-7-{(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octen-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl}-5-heptenoic acid
4-alpha,5-beta(z),6-alpha(1e,3s*)))-r-(1-alph (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2 -oxabicyclo[2.2.1]ht-5-yl]-5-htenoic acid 9,11-DIDEOXY-11Α,9Α-OXYMETHANOPROSTAGLANDIN F2Α,SOLUTION 9,11-DIDEOXY-11ALPHA,9ALPHA-OXYMETHANO 9,11-DIDEOXY-9ALPHA, 11ALPHA-METHANOOXY-PROSTA-5Z,13E-DIEN-OIC ACID 7-(6-(3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)ht-5-yl)-5-htenoicaci(1 9,11-DIDEOXY-11ALPHA,9ALPHA-OXY-METHANOPROSTAGLANDIN F2ALPHA MFCD00135238 9a,11a-methanooxy-15-hydroxyprosta-5,13-dienoicacid U-46619, Thromboxane A2 rector agonist 9,11-dideoxy-11A,9A-oxymethano-*prostaglandin F U 46619,U 9,11-Methanoxy-PGH2 (Z)-7-[(1R,4S)-6β-[(E,S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]ht-5α-yl]-5-htenoic acid 9,11-dideoxy-11α,9α-oxymethanoprostaglandin f2α 9,11-dideoxy-11alpha,9alpha-oxymethano prostaglandin F2A S 11-Methanooxy PGH2 9,11-dideoxy-11alpha,9alpha-oxymethanoprostaglandin F2a 9,11-DIDEOXY-9ALPHA,11ALPHA-METHANOOXYPROSTAGLANDIN F2ALPHA U 46619,(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoicacid 9,11-Methanooxy PGH2 (5Z)-7-[(1R,4S)-6β-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]htan-5α-yl]-5-htenoic acid 9,11-DIDEOXY-9ALPHA,11ALPHA-METHANOOXY PGF2ALPHA U-46619 - - Calbiochem 9,11-DIDEOXY-11A,9A-OXYMETHANO-*PROSTA GLANDIN F2A 5-Htenoic acid, 7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2-oxabicyclo[2.2.1]ht-5-yl]-, (5Z) 11α,9α-oxymethanoprostaglandin H2 9,11-Dideoxy-9α,11α-methanooxyprostaglandin F2α Solution 9,11-DIDEOXY-9ALPHA, 11ALPHA-METHANOOXY-PROSTA-5Z,13E-DIEN-1-OIC ACID U46619, U-46619, U |
| Description | U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist[1]. |
|---|---|
| Related Catalog | |
| Target |
TXA2[1] |
| In Vitro | U-46619 (1 nM-10 μM) causes platelets shape change and aggregation in a concentration-dependent manner, and with EC50s of 0.58 μM and 0.013 μM for aggregation and shape change, respectively[1]. U-46619 (10 nM-10 μM) increases internal Ca2+ concentration ([Ca2+]i) and activates phosphoinositide (PI) hydrolysis in a concentration-dependent manner with a similar concentration-dependency[1]. U-46619 (3 nM-10 μM) also activates GTPase concentration-dependently in the membranes derived from platelets[1]. U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways[2]. |
| In Vivo | U-46619 (5 μg/kg; i.v.) increases blood pressure in male spontaneously hypertensive rats (SHR)[3]. Animal Model: 12-15 weeks-old male and female SHR[2] Dosage: 5 μg/kg Administration: Intravenous injection Result: Induceed a significant increase of MABP after 1 min in male SHR. |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 519.7±30.0 °C at 760 mmHg |
| Molecular Formula | C21H34O4 |
| Molecular Weight | 350.492 |
| Flash Point | 176.1±18.1 °C |
| Exact Mass | 350.245697 |
| PSA | 66.76000 |
| LogP | 3.90 |
| Vapour Pressure | 0.0±3.1 mmHg at 25°C |
| Index of Refraction | 1.548 |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| Symbol |
GHS02, GHS07 |
|---|---|
| Signal Word | Danger |
| Hazard Statements | H225-H319-H336 |
| Supplemental HS | Repeated exposure may cause skin dryness or cracking. |
| Precautionary Statements | P210-P280-P304 + P340 + P312-P305 + P351 + P338-P337 + P313-P403 + P235 |
| Personal Protective Equipment | Eyeshields;Faceshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter |
| Hazard Codes | F;Xi |
| Risk Phrases | R11;R36;R66;R67 |
| Safety Phrases | S16;S26 |
| RIDADR | UN 1231 3/PG 2 |